{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:36:44Z","timestamp":1780047404172,"version":"3.53.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.cpcardiol.2023.101585","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T01:59:23Z","timestamp":1673056763000},"page":"101585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of Monoclonal Antibodies in the Treatment of Atherosclerosis"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3726-7310","authenticated-orcid":false,"given":"Jimmy","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Thakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Jneid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissam","family":"Khalife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2023.101585_bib0001","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41586-020-2993-2","article-title":"ALDH4A1 is an atherosclerosis auto-antigen targeted by protective antibodies","volume":"589","author":"Lorenzo","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0002","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.595819","article-title":"PCSK9 inhibition: insights from clinical trials and future prospects","volume":"11","author":"Katzmann","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0004","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0005","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and Safety of the Proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0006","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of Alirocumab in high cardiovascular risk patients with inadequately controlled Hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0007","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","article-title":"A Phase III randomized trial evaluating Alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","volume":"254","author":"Roth","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0008","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0009","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0010","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab804","article-title":"Alirocumab after acute coronary syndrome in patients with a history of heart failure","volume":"43","author":"White","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0011","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/CIRCULATIONAHA.109.863431","article-title":"Oral Anti-CD3 antibody treatment induces regulatory t cells and inhibits the development of atherosclerosis in mice","volume":"120","author":"Sasaki","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0012","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.106.627430","article-title":"Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice","volume":"114","author":"Steffens","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0013","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1161\/CIRCULATIONAHA.106.615609","article-title":"Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis","volume":"114","author":"van Puijvelde","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0014","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/28204","article-title":"Reduction of atherosclerosis in mice by inhibition of CD40 signaling","volume":"394","author":"Mach","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.cpcardiol.2023.101585_bib0015","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.jacc.2007.07.081","article-title":"Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in Apobec-1\u2212\/\u2212 \/low-density lipoprotein receptor\u2212\/\u2212 mice","volume":"50","author":"Schiopu","year":"2007","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623000026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623000026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:14:19Z","timestamp":1758939259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623000026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0146280623000026"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101585","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Monoclonal Antibodies in the Treatment of Atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101585"}}